



Catapult complete investment into Nottingham based Haemostatix Limited

Catapult Venture Managers Limited has completed an investment into Nottingham based drug development company Haemostatix Limited as part of a £1.2m funding package from its existing investors.

The investment will enable Haemostatix to progress development of HaemoPlax™, a synthetic platelet substitute designed to replace platelets currently obtained from blood donation. Donor platelets, given by transfusion, assist in blood clotting and are currently used to treat cancer and surgical patients at risk from severe bleeding.

Haemostatix also announced the appointment of a new chief executive, Dr Ben Nichols and a new independent non-executive director, Dr Grahaem Brown.

Catapult provides equity capital of between £200k and £2m for growing businesses

For further information please contact: Jonathan Earl on 0116 238 8200 or visit www.catapult-vm.co.uk

East Midlands Office: Malt House, 13 Narborough Wood Park, Desford Road, Enderby, Leicester, LE19 4XT. Tel: 0116 238 8200
Email: mail@catapult-vm.co.uk
www.catapult-vm.co.uk

West Midlands Office: One Victoria Square, Birmingham, B1 1BD. Tel: 0121 616 0180
Email: mail@catapult-vm.co.uk
www.catapult-vm.co.uk

Investors in our funds include:



Catapult Venture Managers Limited. Registered in England and Wales No: 03818199. Registered Office: Malt House, 13 Narborough Wood Business Park, Desford Road, Enderby, Leicester LE19 4XT. Tel: 0116 238 8200. Fax: 0116 239 6997. Catapult Venture Managers Limited is authorised and regulated by the Financial Services Authority.